Testing bispecific antibodies using human tumour tissue on chip v2

  • Research type

    Research Study

  • Full title

    Testing the effects of bispecific antibodies targeting markers expressed by tumours and immune cells using human tumour tissue on chip

  • IRAS ID

    263319

  • Contact name

    John Greenman

  • Contact email

    j.greenman@hull.ac.uk

  • Sponsor organisation

    University of Hull

  • Duration of Study in the UK

    1 years, 11 months, 31 days

  • Research summary

    The aim of the work is to test two novel antibody molecules made by F-star, a pharmaceutical company, against tissue biopsies taken from cancer patients and maintained alive in a microfluidic device. These novel antibodies have been engineered to effect the tumour and the immune cells, and studying their effects on human tissue will provide unique information about how they work. This is a preclinical laboratory investigation to study how the novel drugs (antibodies) work.
    The use of the microfluidic devices (chips) allows human tissue to be studied rather than rely on animal models or tumour cell lines; neither of which fully represent the human situation.

  • REC name

    Yorkshire & The Humber - South Yorkshire Research Ethics Committee

  • REC reference

    19/YH/0202

  • Date of REC Opinion

    24 Jul 2019

  • REC opinion

    Further Information Favourable Opinion